CD109 and cancer: Our findings establish CD109 as an essential regulator of IL-6-mediated oncogenic activity promoting cancer cell stemness and antioxidant state in SCC cells, providing mechanistic insights into IL-6-mediated cell survival and resistance to therapy in SCC.